{"id":67091,"date":"2026-06-02T14:26:21","date_gmt":"2026-06-02T06:26:21","guid":{"rendered":"https:\/\/flcube.com\/?p=67091"},"modified":"2026-06-02T14:26:21","modified_gmt":"2026-06-02T06:26:21","slug":"sino-biopharmaceuticals-saitanxin-shows-32-4-response-rate-in-cdk4-6-inhibitor-resistant-breast-cancer-at-asco-2026","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67091","title":{"rendered":"Sino Biopharmaceutical&#8217;s Saitanxin Shows 32.4% Response Rate in CDK4\/6 Inhibitor-Resistant Breast Cancer at ASCO 2026"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd.<\/strong> (CTTQ), a subsidiary of <strong>Sino Biopharmaceutical Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1177:HKG\">HKG: 1177<\/a>), presented compelling Phase II clinical data at the <strong>2026 American Society of Clinical Oncology (ASCO) Annual Meeting<\/strong> for <strong>Saitanxin (culmerciclib)<\/strong>, a <strong>CDK2\/4\/6 inhibitor<\/strong>, in combination with fulvestrant for patients with <strong>HR-positive, HER2-negative advanced breast cancer<\/strong> who had progressed on prior CDK4\/6 inhibitor plus endocrine therapy.<\/p>\n\n\n\n<h2 id=\"h-clinical-trial-results-phase-ii-study\" class=\"wp-block-heading\">Clinical Trial Results \u2013 Phase II Study<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result<\/th><th>Confidence Interval<\/th><th>Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Objective Response Rate (ORR)<\/strong><\/td><td><strong>32.4%<\/strong><\/td><td>17.4\u201350.5%<\/td><td>p&lt;0.0001 (primary endpoint met)<\/td><\/tr><tr><td><strong>Disease Control Rate (DCR)<\/strong><\/td><td><strong>88.2%<\/strong><\/td><td>72.6\u201396.7%<\/td><td>Clinically meaningful<\/td><\/tr><tr><td><strong>Clinical Benefit Rate (CBR)<\/strong><\/td><td><strong>82.4%<\/strong><\/td><td>65.5\u201393.2%<\/td><td>Substantial patient benefit<\/td><\/tr><tr><td><strong>Time to Response (TTR)<\/strong><\/td><td><strong>3.7 months<\/strong> (median)<\/td><td>\u2014<\/td><td>Rapid onset of activity<\/td><\/tr><tr><td><strong>10-Month PFS Rate<\/strong><\/td><td><strong>61.8%<\/strong><\/td><td>42.3\u201376.4%<\/td><td>Promising sustained disease control<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>34 efficacy-evaluable patients<\/td><td>Heavily pre-treated<\/td><td>CDK4\/6i-resistant setting<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The study addresses a critical unmet need in breast cancer treatment\u2014patients who have exhausted standard CDK4\/6 inhibitor therapy and represent one of the most challenging populations to treat effectively.<\/p>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Culmerciclib (Saitanxin) \u2013 novel CDK2\/4\/6 inhibitor<\/li>\n\n\n\n<li><strong>Target Rationale:<\/strong> Simultaneous inhibition of CDK2, CDK4, and CDK6 overcomes resistance mechanisms that develop against selective CDK4\/6 inhibitors<\/li>\n\n\n\n<li><strong>Combination Partner:<\/strong> Fulvestrant (estrogen receptor degrader)<\/li>\n\n\n\n<li><strong>Patient Population:<\/strong> HR+\/HER2- advanced breast cancer post-CDK4\/6 inhibitor failure<\/li>\n\n\n\n<li><strong>Safety Profile:<\/strong> Consistent with prior studies; no new safety signals observed<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-competitive-landscape\" class=\"wp-block-heading\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>CDK4\/6 Inhibitor Resistance<\/strong><\/td><td>~70% of HR+ breast cancer patients eventually progress on CDK4\/6 inhibitors; limited effective subsequent options<\/td><\/tr><tr><td><strong>Current Treatment Options<\/strong><\/td><td>Chemotherapy, PI3K inhibitors, SERDs; generally lower response rates and higher toxicity<\/td><\/tr><tr><td><strong>Saitanxin Differentiation<\/strong><\/td><td>First-in-class CDK2\/4\/6 triple inhibition approach specifically designed to overcome CDK4\/6i resistance<\/td><\/tr><tr><td><strong>Market Opportunity<\/strong><\/td><td>Estimated 45,000-50,000 CDK4\/6i-resistant HR+ breast cancer patients annually in major markets<\/td><\/tr><tr><td><strong>Competitive Environment<\/strong><\/td><td>Multiple companies developing next-generation CDK inhibitors; Saitanxin among first to report robust clinical data in resistant setting<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-implications-amp-development-outlook\" class=\"wp-block-heading\">Strategic Implications &amp; Development Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Pathway:<\/strong> Strong Phase II data supports potential accelerated approval discussions with FDA and NMPA<\/li>\n\n\n\n<li><strong>Commercial Premium:<\/strong> High response rate in resistant population supports significant pricing power<\/li>\n\n\n\n<li><strong>Global Expansion:<\/strong> ASCO presentation validates international development strategy for Chinese-developed oncology asset<\/li>\n\n\n\n<li><strong>Pipeline Validation:<\/strong> Success reinforces Sino Biopharmaceutical&#8217;s oncology innovation capabilities beyond traditional generics<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Phase III confirmatory trial likely to initiate based on compelling Phase II results<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The 32.4% ORR represents a substantial improvement over historical benchmarks in this heavily pre-treated population, where response rates typically range from 10-20% with available therapies.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical trial results, regulatory pathways, and commercial expectations for Saitanxin. Actual results may differ due to risks including clinical trial variability, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060200026_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026060200026_c.\"><\/object><a id=\"wp-block-file--media-6245abe9-e4eb-45cd-987e-bb9e324f5907\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060200026_c.pdf\">2026060200026_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060200026_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-6245abe9-e4eb-45cd-987e-bb9e324f5907\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG:&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[106,16,661,17,908,313],"class_list":["post-67091","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-academic-conference","tag-cancer","tag-chia-tai-tianqing-pharmaceutical","tag-clinical-trial-results","tag-hkg-1177","tag-sino-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sino Biopharmaceutical&#039;s Saitanxin Shows 32.4% Response Rate in CDK4\/6 Inhibitor-Resistant Breast Cancer at ASCO 2026 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG: 1177), presented compelling Phase II clinical data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting for Saitanxin (culmerciclib), a CDK2\/4\/6 inhibitor, in combination with fulvestrant for patients with HR-positive, HER2-negative advanced breast cancer who had progressed on prior CDK4\/6 inhibitor plus endocrine therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67091\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sino Biopharmaceutical&#039;s Saitanxin Shows 32.4% Response Rate in CDK4\/6 Inhibitor-Resistant Breast Cancer at ASCO 2026\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG: 1177), presented compelling Phase II clinical data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting for Saitanxin (culmerciclib), a CDK2\/4\/6 inhibitor, in combination with fulvestrant for patients with HR-positive, HER2-negative advanced breast cancer who had progressed on prior CDK4\/6 inhibitor plus endocrine therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67091\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-02T06:26:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67091#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67091\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sino Biopharmaceutical&#8217;s Saitanxin Shows 32.4% Response Rate in CDK4\\\/6 Inhibitor-Resistant Breast Cancer at ASCO 2026\",\"datePublished\":\"2026-06-02T06:26:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67091\"},\"wordCount\":444,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Academic conference\",\"Cancer\",\"Chia Tai Tianqing Pharmaceutical\",\"Clinical trial results\",\"HKG: 1177\",\"Sino Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67091#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67091\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67091\",\"name\":\"Sino Biopharmaceutical's Saitanxin Shows 32.4% Response Rate in CDK4\\\/6 Inhibitor-Resistant Breast Cancer at ASCO 2026 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-02T06:26:21+00:00\",\"description\":\"Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG: 1177), presented compelling Phase II clinical data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting for Saitanxin (culmerciclib), a CDK2\\\/4\\\/6 inhibitor, in combination with fulvestrant for patients with HR-positive, HER2-negative advanced breast cancer who had progressed on prior CDK4\\\/6 inhibitor plus endocrine therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67091#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67091\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67091#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sino Biopharmaceutical&#8217;s Saitanxin Shows 32.4% Response Rate in CDK4\\\/6 Inhibitor-Resistant Breast Cancer at ASCO 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sino Biopharmaceutical's Saitanxin Shows 32.4% Response Rate in CDK4\/6 Inhibitor-Resistant Breast Cancer at ASCO 2026 - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG: 1177), presented compelling Phase II clinical data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting for Saitanxin (culmerciclib), a CDK2\/4\/6 inhibitor, in combination with fulvestrant for patients with HR-positive, HER2-negative advanced breast cancer who had progressed on prior CDK4\/6 inhibitor plus endocrine therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67091","og_locale":"en_US","og_type":"article","og_title":"Sino Biopharmaceutical's Saitanxin Shows 32.4% Response Rate in CDK4\/6 Inhibitor-Resistant Breast Cancer at ASCO 2026","og_description":"Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG: 1177), presented compelling Phase II clinical data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting for Saitanxin (culmerciclib), a CDK2\/4\/6 inhibitor, in combination with fulvestrant for patients with HR-positive, HER2-negative advanced breast cancer who had progressed on prior CDK4\/6 inhibitor plus endocrine therapy.","og_url":"https:\/\/flcube.com\/?p=67091","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-02T06:26:21+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67091#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67091"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sino Biopharmaceutical&#8217;s Saitanxin Shows 32.4% Response Rate in CDK4\/6 Inhibitor-Resistant Breast Cancer at ASCO 2026","datePublished":"2026-06-02T06:26:21+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67091"},"wordCount":444,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Academic conference","Cancer","Chia Tai Tianqing Pharmaceutical","Clinical trial results","HKG: 1177","Sino Biopharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67091#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67091","url":"https:\/\/flcube.com\/?p=67091","name":"Sino Biopharmaceutical's Saitanxin Shows 32.4% Response Rate in CDK4\/6 Inhibitor-Resistant Breast Cancer at ASCO 2026 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-02T06:26:21+00:00","description":"Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG: 1177), presented compelling Phase II clinical data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting for Saitanxin (culmerciclib), a CDK2\/4\/6 inhibitor, in combination with fulvestrant for patients with HR-positive, HER2-negative advanced breast cancer who had progressed on prior CDK4\/6 inhibitor plus endocrine therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67091#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67091"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67091#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sino Biopharmaceutical&#8217;s Saitanxin Shows 32.4% Response Rate in CDK4\/6 Inhibitor-Resistant Breast Cancer at ASCO 2026"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67091","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67091"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67091\/revisions"}],"predecessor-version":[{"id":67093,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67091\/revisions\/67093"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67091"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67091"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67091"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}